New research shows that the the longest-acting injectable PrEP, shows no adverse interactions with hormone therapy for trans ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Dec 15 (Reuters) - Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...

Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab after an independent data monitoring committee said the drug will fail in ...